FDA Approves First Oral Preventive Treatment for Pediatric HAE, With Jolanta Bernatoniene, PhD

 has approved berotralstat (ORLADEYO) oral pellets for long-term prophylaxis of 

 in children aged 2 to 11 years. The approval, announced by BioCryst on December 12, 2025, marks the first and only oral, once-therapy indicated for long-term prevention of HAE attacks in this age group.

“Up until now, we had huge unmet needs for this patient group,” Jolanta Bernatoniene, PhD, lead investigator of the APeX-P trial in the United Kingdom and from Bristol Royal Hospital for Children, told 

“Those patients were managed with injections, and as you can imagine, those injections caused significant negative impact on the patients, on the families, [and] was difficult to manage from clinical perspectives.”

Historically, long-term prophylaxis in children relied on subcutaneous monoclonal antibodies, such as lanadelumab or intravenous C1 esterase inhibitor concentrates, both of which can be challenging for pediatric patients and caregivers. Frequent injections are associated with needle anxiety, treatment reluctance, and substantial caregiver burden.

“[The berotralstat approval is a] significant achievement because these are little sprinkles, very easy to administer,” Bernatoniene continued.

Berotralstat’s oral formulation offers a meaningful shift in care. The medication is administered as small pellets that can be sprinkled onto non-acidic food, simplifying dosing and improving treatment acceptance. Berotralstat is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein that can prevent HAE attacks by reducing the activity of the plasma kallikrein.

The FDA decision was supported by efficacy and safety data from the APeX-P trial, which evaluated weight-based dosing across pediatric age groups. Interim and long-term results demonstrated rapid and sustained reductions in HAE attack rates, with mean monthly attack rates reduced to 0, and more than half of patients remaining attack-free for up to 1 year. The interim data showed that, at a steady state, berotralstat reached peak concentration at a median of 3.9 hours (range, 0.9 – 6.0 hours).

No clinically meaningful differences in efficacy were observed across age, sex, or disease severity subgroups. Additionally, no cardiovascular safety concerns, including QT prolongation, were observed in the pediatric population, according to Bernatoniene. Ongoing extension studies will continue to monitor long-term safety and effectiveness for up to 5 years.

Clinicians anticipate that berotralstat’s approval will prompt updates to national and international HAE treatment guidelines and influence first-line prophylactic strategies for children, particularly younger patients for whom injectable therapies pose significant challenges.

When asked how the berotrolstat approval may impact future drug development, Bernatoniene said that there is always room for improvement. Although berotralstat is effective and easy to administer, it remains a once-daily treatment.

“[It] would be easier for the patients if we can administer [the treatment] less frequently, so perhaps oral formulation, but once a month or once every 3 months,” she said. “This is still [a] daily medication to remember for the family when they have very busy lives. Every drug will have its niche, so the indications and prescribing [have] to be discussed… in partnership with children age-appropriate and their families.”

Bernatoniene has no relevant disclosures.

Derman C. FDA Approves Oral Berotralstat for Children Aged 2 – 11 Years with HAE. HCPLive. December 12, 2025. Accessed January 15, 2026. 

https://www.hcplive.com/view/fda-approves-oral-berotralstat-children-aged-2-11-years-hae

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years. BioCryst. Published December 12, 2025. Accessed December 12, 2025. 

https://ir.biocryst.com/news-releases/news-release-details/biocryst-announces-fda-approval-orladeyor-berotralstat-oral

Videos

Berotralstat becomes the first once-daily oral prophylactic option for long-term prevention of hereditary angioedema in children aged 2–11 years.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

FDA News

FDA Approves Oral Berotralstat for Pediatric HAE, With Jolanta Bernatoniene, PhD

Frances Lee, MD, is an assistant professor of medicine in the division of liver diseases at Mount Sinai.

Addressing Stigma and Advancing Care in Alcohol-Associated Liver Disease, With Frances Lee, MD

Alcohol-associated liver disease (ALD) remains a major and growing cause of liver-related morbidity and mortality, yet it is often approached through an oversimplified and stigmatized lens.

Misconceptions about who develops the disease, why it occurs, and how it should be treated continue to influence both patient engagement and clinical decision-making. As understanding of ALD evolves, there is increasing recognition that effective care extends beyond managing liver injury alone and requires a more nuanced, multidisciplinary approach.

“[It] is a really interesting topic because there are a lot of misconceptions both on the patient side and on the clinician side,” Frances Lee, MD, an assistant professor of medicine in the division of liver diseases at Mount Sinai, told 

, describing misinformed beliefs about comorbid alcohol use disorder and the subsequent stigmatization this thought process introduces.

For patients, she says this stigma may discourage engagement with care or delay presentation altogether, while for clinicians, it can unconsciously narrow how the disease is approached and managed.

Lee goes on to emphasize that ALD care involves more than just treating the liver disease–it also requires addressing factors impacting the patient’s drinking patterns. Because of this, she says multidisciplinary care is essential, like that provided by Mount Sinai’s Respectful and Equitable Access to Comprehensive Healthcare (REACH) Program.

Co-located within Mount Sinai Hospital’s Internal Medicine Associates, REACH provides a patient-centered, harm reduction approach to primary care for persons who use alcohol and other drugs, and for individuals living with hepatitis C virus infection. Similar programs exist at other institutions, like Massachusetts General Hospital’s Long-term Individualized Follow-up after Transplant (LIFT) Clinic for the the prevention and management of alcohol relapse in high-risk liver transplant recipients.

Beyond multidisciplinary care, Lee also looks ahead to the future of pharmacotherapy for ALD, describing her excitement about trials exploring GLP-1s and siRNA molecules for this indication.

“Right now, the current medications that we use for alcohol-associated liver disease are really medications for alcohol use disorder and alcohol use cravings, so to be able to offer patients a liver-specific therapy for their disease courses in the future is very exciting,” she said.

Editors’ Note: Lee does not report any relevant disclosures.

Mount Sinai. Respectful and Equitable Access to Comprehensive Healthcare (REACH) Program. Accessed January 15, 2026. 

https://www.mountsinai.org/care/primary-care/upper-east-side/ima/reach

Zhang W. Preventing Alcohol Relapse After Liver Transplant, with Wei Zhang, MD, PhD. 

. May 5, 2025. Accessed January 15, 2026. 

https://www.hcplive.com/view/preventing-alcohol-relapse-after-liver-transplant-with-wei-zhang-md-phd

Lee describes misconceptions about ALD, the importance of multidisciplinary care, and what the future of pharmacotherapy for this disease may hold.

Hepatology

Guy Young, MD, is the director of the Hemostasis and Thrombosis program at Children’s Hospital Los Angeles and professor of pediatrics at Keck School of Medicine of USC.

Ongoing Trial Investigates Switching from Emicizumab to Fitusiran in Hemophilia A, With Guy Young, MD

SWITCH, an ongoing exploratory, open-label, single-arm Phase 1 study, is actively investigating the process of transitioning from emicizumab to fitusiran for the treatment of severe 

Hemophilia A results from a mutation in the genes that encode clotting factor VIII, which leads to a disruption in the contact activation pathway of coagulation. Most patients are male, due to the condition’s X-linked recessive inheritance pattern. Patients with severe hemophilia A require consistent, regular replacement therapy with FVIII to maintain factor levels at 1-3% of the normal value, to prevent bleeding diathesis and its complications.

Current therapies are produced either from human plasma or recombinant DNA technology using human and nonhuman cells. Protein modification techniques have also been employed to extend the plasma half-life of recombinant clotting factors, which reduces the number and frequency of injections. However, patients often develop neutralizing antibodies against FVIII, the incidence of which is roughly 20-30% in patients with severe hemophilia A.

“Unlike medications like Factor, which have a short half-life, switching from emicizumab to another drug is tricky because it has a longer half-life,” Guy Young, MD, director of the Hemostasis and Thrombosis program at Children’s Hospital Los Angeles and professor of pediatrics at Keck School of Medicine of USC, told 

 in an exclusive interview. “It takes weeks to months before emicizumab washes fully out of your system. We don’t want the full amount of emicizumab in the blood when we start fitusiran, because it could increase the risk of thrombotic events, so it could compromise patient safety.”

SWITCH consists of a 60-day screening period, a 2-month pre-fitusiran treatment period to allow the washout of emicizumab, and an 18-month fitusiran prophylaxis period. The washout strategy was determined via a combination of modeling and simulation data to predict factor VIII-like activity equivalence. A population-pharmacokinetic model was utilized to draw a direct link between emicizumab exposure during the washout period and factor VIII-like activity.

Young and colleagues conducted simulations of antithrombin levels in participants receiving fitusiran, inputting this data into a quantitative systems pharmacology model to predict factor VIII-like activity in people with severe hemophilia A. Through this, the total FVIII-like activity from both emicizumab and fitusiran was assumed to be additive, implying a total factor VIII-like activity of <50% with fitusiran administration around 2 months after the last emicizumab dose.

During the trial, participants will start fitusiran treatment once every 2 months (Q2M), although investigators may escalate or de-escalate the dose to target antithrombin activity levels of 15-35% and maintain sufficient bleed protection. The first 3 sentinel participants are treated in a stepwise fashion, which requires 1 patient to complete 1 month of fitusiran treatment before the next participant may begin.

After the final dose, antithrombin activity will be monitored monthly during the 6-month antithrombin follow-up period. Investigators have established a primary endpoint of incidence, severity, and seriousness of adverse events from day 1 to month 4 of fitusiran treatment. Secondary endpoints include lab assessments of peak thrombin generation and antithrombin levels from day 1 to month 4, emicizumab plasma concentrations up to the end of washout, and incidence, severity, and seriousness of adverse events from day 1 to month 18 of fitusiran treatment. Young and colleagues also plan to monitor health-related quality of life measures from baseline to the end of the study period, change in participant joint health, and annualized bleeding rate for the 14-month extension.

A total of 15-20 male patients aged ≥18 years have been enrolled in the study so far, all with severe hemophilia A and both with and without inhibitors. However, enrollment is still ongoing.

“If you want to be completely safe from a thrombotic standpoint, you can stop emicizumab, wait 6 months for it to be fully washed out, and then you could start the fitusiran,” Young said. “But the problem with that is that it’ll leave the patient unprotected from bleeding for at least a 2, 3, maybe even 4-month period, and that’s the last thing we want to do. The question that the SWITCH study is aiming to answer is when is the right time to stop emicizumab and start fitusiran, to thread that needle?”

Editor’s Note: Young reports disclosures with BioMarin, Genentech/Roche, Pfizer, CSL Behring, ASC Biotherapeutics, Alnylam, and others.

Young G, Kaddi C, Ali S, et al. Evaluating the safety and tolerability of switching from emicizumab to fitusiran prophylaxis in adult males with severe hemophilia A, with or without inhibitors: Switch Study, a trial in progress. Blood. 2025;146(Supplement 1):3076-3076. 

Wichaiyo S. Advances in Development of Drug Treatment for Hemophilia with Inhibitors. ACS Pharmacol Transl Sci. 2024;7(12):3795-3803. Published 2024 Nov 8. 

The SWITCH phase 1 trial aims to determine the optimal time to switch medications to minimize thrombotic risk and avoid leaving patients untreated.

Hematology

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

A newly developed risk score using national Organ Procurement and Transplantation Network (OPTN) data demonstrated fair accuracy in predicting short-term mortality among > 147,000 adult kidney transplant waitlist candidates.

The Mortality Estimation in Renal Disease (MERD) score aims to help guide the allocation of expanded criteria donor kidneys to candidates at the highest mortality risk, while acknowledging further prospective validation and model refinement are warranted.

“In this study, we aim to develop an index score utilizing variables from the OPTN database to predict mortality among adult kidney transplant candidates within 3 years of being on the waitlist,” wrote Aisha Albu Mustaf, MBBS, University of Baghdad College of Medicine, and colleagues.

Kidney transplant candidates face a risk of mortality while on the waitlist before receiving an allograft. Despite existing risk prediction tools, there is currently no widely adopted system that reliably identifies patients at the highest risk of waitlist mortality, particularly given the ongoing shortage of living donor organs.

To address this, investigators conducted a retrospective analysis of adult kidney transplant candidates using data from the OPTN database between 2018 and 2023.

Investigators evaluated 16 demographic and clinical variables using univariate logistic regression to identify factors associated with kidney transplant waitlist mortality. Variables demonstrating statistical significance were subsequently entered into a multivariable logistic regression model to develop the MERD score, a predictive tool designed to estimate short-term waitlist mortality risk. Model performance was assessed using receiver operating characteristic (ROC) curve analysis, with discrimination quantified by the C-statistic.

Investigators randomly divided kidney transplant candidates into training and validation cohorts to evaluate internal validity. Mortality risk stratification was further examined by categorizing candidates into MERD score quartiles, with cumulative mortality compared across quartiles over time.

The study included data from 147,307 adults ≥ 18 years of age who were waitlisted kidney transplant candidates. The age of the patient population ranged between 45 and 54 years (21.21%). Only 6.67% of candidates were ≥ 70 years, while 9.46% were young adults aged 18 to 34 years.

Among the adult kidney transplant candidates included from the OPTN database, Mustaf and colleagues identified 10 variables as significant predictors of waitlist mortality and incorporated them into the Mortality Estimation in Renal Disease (MERD) score. These included age, ABO blood type, ethnicity, dialysis duration, presence of peripheral vascular disease, serum albumin level, functional status, prior kidney malignancy, primary etiology of kidney disease, and insurance type.

The investigators reported age and etiology of kidney disease accounted for the largest proportion of the model’s predictive contribution. In multivariable analyses, Mustaf and colleagues found young adults 18 to 34 years, blood types A and AB, African American, Hispanic Latino, and Asian ethnicity relative to White ethnicity, preserved functional status, and higher serum albumin levels were associated with lower waitlist mortality.

In contrast, age >55 years, White ethnicity, longer dialysis duration, reduced functional status, low albumin levels, diabetes, and the presence of peripheral vascular disease were associated with an increased risk of mortality.

According to the investigators, the MERD score demonstrated fair discriminatory performance for predicting waitlist mortality, with an area under the curve (AUC) of 0.6657 in the training cohort and 0.6580 in the validation cohort. Model performance was consistent between cohorts, supporting internal validity.

When candidates were stratified by MERD score quartiles, the investigators observed cumulative mortality increased progressively with higher scores. Candidates in the highest MERD quartile experienced the greatest proportion of mortality over follow-up, indicating the model’s ability to stratify short-term mortality risk among kidney transplant waitlist candidates.

“The MERD score provides proof of concept for short-term mortality prediction for kidney transplant waitlist candidates. Further prospective validation and model refinement are warranted,” concluded investigators.

Albu Mustaf A, Ramirez J, Montgomery A, Henry G, Rana A. Mortality Estimation in Renal Disease (MERD Score): A Model Predicting Waitlist Mortality in Kidney Transplant Candidates. 

. Published online January 8, 2026. doi:https://doi.org/10.1016/j.transproceed.2025.11.010

Bergler T, Hutchinson JA. Tools for Predicting Kidney Transplant Outcomes. 

. 2017;101(9):1958-1959. doi:https://doi.org/10.1097/tp.0000000000001891

Articles

A newly developed risk score, the Mortality Estimation in Renal Disease (MERD) score, utilizes data from the Organ Procurement and Transplantation Network to predict short-term mortality among adult kidney transplant waitlist candidates. The study analyzed over 147,000 candidates, identifying ten significant predictors of mortality, including age, blood type, and dialysis duration. The MERD score demonstrated fair accuracy, with an AUC of 0.6657 in the training cohort. Further validation and refinement are needed to enhance its utility in guiding donor kidney allocation to high-risk candidates.

The Mortality Estimation in Renal Disease (MERD) score may help identify transplant candidates at highest risk of waitlist mortality.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

New MERD Risk Score Predicts Mortality for Kidney Transplant Waitlist Patients

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Ritlecitinib is effective across various subgroups of patients with 

This drug was evaluated in a recent study authored by investigators such as Yuji Yamaguchi, the Executive Director of Clinical Research at Pfizer. Yamaguchi and colleagues highlighted ritlecitinib’s use as an oral, selective, dual inhibitor of JAK3 and the TEC family kinases.

The drug is currently under phase 3 investigation for its use in treating non-segmental vitiligo. Prior research noted by the investigators points to ritlecitinib’s demonstrated efficacy and safety in a phase 2b analysis.

“...[Data] are limited on how other demographic and clinical characteristics affect the efficacy of ritlecitinib in patients with NSV,” the investigative team wrote.

 “This post hoc analysis explored the efficacy of ritlecitinib in patients with NSV stratified by baseline demographic and clinical characteristics.”

Previous information reported in a phase 2b clinical study was used in this post hoc evaluation (NCT03715829). This trial had looked at treatment with ritlecitinib among adult patients living with active non-segmental vitiligo. The study had consisted of a 24-week dose-ranging phase, a period then followed by a 24-week extension phase. Those between the ages of 18 - 65 years of age were deemed eligible, provided they had active non-segmental vitiligo.

The presence of patient disease was defined by the observation of at least a single active vitiligo-related lesion. In terms of activity criteria, examples included newly appearing or enlarging lesions within the prior 3 months and/or confetti-like, trichrome, or Koebner lesions. Yamaguchi et al did not include historical isomorphic reactions.

All of those involved as participants were also required to have facial involvement of their vitiligo, with the disease affecting .25% of body surface area (BSA) at minimum. In the study’s initial 24-week dose-ranging period, those evaluated were treated with a maintenance dose of ritlecitinib at 50 mg once-per-day. The drug was administered either alone or after the conclusion of a 4-week loading regimen of 200 mg or 100 mg, taking place once daily.

Within the investigators’ subsequent extension period, trial subjects at Week 16 who had not succeeded in attaining at least an improvement of 50% from the point of baseline in their Total Vitiligo Area Scoring Index (T-VASI) were shifted to 1 of several different potential treatment strategies. These strategies would include open-label ritlecitinib 200/50 mg combined with narrowband UVB phototherapy, open-label brepocitinib, or blinded ritlecitinib on a 200/50 mg dosing regimen.

In Yamaguchi and coauthors’ present analysis, they focused on individuals featured in the extension phase who were randomized to the blinded ritlecitinib 200/50 mg arm of the study. In this particular cohort, trial participants were given a 200-mg loading dose over 4 weeks followed by 50 mg on a once-per-day regimen. Efficacy of ritlecitinib’s use was assessed by the investigators through a determination of the percentage of individuals attaining at least a 75% improvement from the point of baseline on their centrally read Facial Vitiligo Area Scoring Index (F-VASI75) score at the 24 and 48-week marks. Outcomes were then further evaluated across baseline demographic and clinical subgroups.

Findings on Ritlecitinib in Non-Segmental Vitiligo

There were 184 patients in total from the dose-ranging phase and 90 individuals from the extension phase who Yamaguchi and colleagues involved in their post hoc analysis. The proportion of those showing a F-VASI75 score was 8.7% at 24 weeks and rose to 26.7% by the 48-week mark. The investigative team noted, across all of the subgroups of patients with non-segmental vitiligo, ritlecitinib demonstrated clinically meaningful levels of facial re-pigmentation.

By the 24-week mark, the team highlighted numerical but statistically non-significant differences in subjects’ responses, specifically among certain subgroups. Yamaguchi et al observed increased rates of disease response among men versus women. These greater rates were also observed in individuals with Fitzpatrick skin types III–VI as opposed to I–II.

Other subgroups in this category were those with facial BSA involvement of at least 0.5% versus less than 0.5%, patients without leukotrichia versus those with leukotrichia, and treatment-naïve individuals versus those previously given treatment. These subgroup differences were noted by the team as less apparent by the 48-week mark.

By the extension period’s conclusion, there remained only modest, non-significant trends. These data favored patients with a body mass index of 30 kg/m² or lower, individuals without leukotrichia, and those without comorbid conditions. There were no notable distinctions detected by the investigative team across the remaining baseline characteristics.

“Overall, ritlecitinib was efficacious across different patient subgroups up to 48 weeks,” the team concluded.

 “These findings contribute to the understanding of how demographic and clinical characteristics affect clinical response to ritlecitinib in patients with active vitiligo, potentially guiding more personalized therapeutic approaches and improving patient outcomes.”

Pandya AG, Hamzavi I, Yamaguchi Y, et al. Efficacy of Ritlecitinib for Vitiligo Treatment Stratified by Baseline Demographic and Clinical Characteristics: Post Hoc Analysis of a Phase 2b Study. JEADV Clinical Practice. 

Ezzedine K, Peeva E, King B, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. J Am Acad Dermatol. 2023 Feb;88(2):395-403. doi: 10.1016/j.jaad.2022.11.005. Epub 2022 Nov 9. Erratum in: J Am Acad Dermatol. 2023 Sep;89(3):639. doi: 10.1016/j.jaad.2023.04.001. PMID: 36370907.

Ritlecitinib has shown efficacy in treating non-segmental vitiligo across various patient subgroups up to 48 weeks. The drug, a selective dual inhibitor of JAK3 and TEC family kinases, is under phase 3 investigation. A post hoc analysis of a phase 2b study evaluated its efficacy based on baseline demographic and clinical characteristics. Results indicated clinically meaningful facial re-pigmentation, with some subgroup differences noted at 24 weeks but less apparent by 48 weeks. These findings may guide personalized therapeutic approaches and improve patient outcomes.

Ritlecitinib was evaluated for the treatment of non-segmental vitiligo (NSV) in different subgroups, stratified by demographics as well as various clinical characteristics.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Ritlecitinib Efficacious for Non-Segmental Vitiligo Across Various Subgroups

Video Series

Clinical Experience with Tocilizumab and Upadacitinib in GCA Treatment 

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Post-hoc analysis of the FLAME trial shows treatment discontinuation in COPD is associated with transient withdrawal effects and increased exacerbation risk.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Stopping Inhaled Corticosteroids or LAMA in COPD Linked to Early Exacerbations

Reflecting on the Trial Landscape in GCA and History of Approved Agents 

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Susan Weiner, MS, to discuss the recently released US Dietary Guidelines.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Type 1 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Diabetes Dialogue: Reviewing the New US Dietary Guidelines with Susan Weiner, MS

Once-daily treatment of atopic dermatitis with oral ICP-332 showed a favorable safety profile and meaningful efficacy in a new study.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

ICP-332 Effective, Safe for Treating Moderate to Severe Atopic Dermatitis

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Experts discussed how biologics revolutionize asthma and COPD management, emphasizing personalized treatment strategies and proactive care.

From GOLD to Ground Level: Navigating Biologic Use in COPD Care

A retrospective analysis does not link gentamicin with decreased risks of urinary tract infections after kidney transplantation.


Chronic Kidney Disease

Gentamicin May Not Reduce Post Kidney Transplant Urinary Tract Infection Risk 

A study found that bronchodilator responsiveness more accurately forecasts FEV₁ decline and COPD development than polygenic risk scores.

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Jamie Scott, PhD, is an EiC senior chemist at the University of Edinburgh.

Scott describes current unmet needs in IBD diagnosis and monitoring but points to the potential of a new GzmA activity-based optical assay.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Advancing Noninvasive Diagnostics for Inflammatory Bowel Disease, With Jamie Scott, PhD

Despite an OTC approval in 2023, recent data highlights a carry rate of only 10% in the general population.

Internal Medicine

Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.

Family Medicine

Family Medicine condition center page, resources on the topics of medical news and expert insight into family care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on Family medicine research, treatment, and drug development.

Latest News

FDA Approves Oral Berotralstat for Pediatric HAE, With Jolanta Bernatoniene, PhD

Addressing Stigma and Advancing Care in Alcohol-Associated Liver Disease, With Frances Lee, MD

Ongoing Trial Investigates Switching from Emicizumab to Fitusiran in Hemophilia A, With Guy Young, MD

New MERD Risk Score Predicts Mortality for Kidney Transplant Waitlist Patients

Ritlecitinib Efficacious for Non-Segmental Vitiligo Across Various Subgroups